KR950703948A - 피부를 통해 피소스티그민을 투여하기 위한 경피치료계, 및 이러한 계의 제조방법(transdermal therapeutic system for administering physostigmin through the skin〈 and a method of producing the system) - Google Patents

피부를 통해 피소스티그민을 투여하기 위한 경피치료계, 및 이러한 계의 제조방법(transdermal therapeutic system for administering physostigmin through the skin〈 and a method of producing the system) Download PDF

Info

Publication number
KR950703948A
KR950703948A KR1019950701873A KR19950701873A KR950703948A KR 950703948 A KR950703948 A KR 950703948A KR 1019950701873 A KR1019950701873 A KR 1019950701873A KR 19950701873 A KR19950701873 A KR 19950701873A KR 950703948 A KR950703948 A KR 950703948A
Authority
KR
South Korea
Prior art keywords
transdermal therapeutic
layer
therapeutic system
storage layer
weight
Prior art date
Application number
KR1019950701873A
Other languages
English (en)
Other versions
KR100254573B1 (ko
Inventor
도이러 로타르
힐레 토마스
프로피틀리히 토마스
슈타니슐라우즈 프릿츠
발터 케르슈텐
Original Assignee
카를하인쯔 쉬슬러, 다이터 슈나이더
클링에 파르마 게엠베하
베르너 베슬링, 프랑크 베허
엘테에스 로만 테라피-지스테메 게엠베하 운트 콤파니 카게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 카를하인쯔 쉬슬러, 다이터 슈나이더, 클링에 파르마 게엠베하, 베르너 베슬링, 프랑크 베허, 엘테에스 로만 테라피-지스테메 게엠베하 운트 콤파니 카게 filed Critical 카를하인쯔 쉬슬러, 다이터 슈나이더
Publication of KR950703948A publication Critical patent/KR950703948A/ko
Application granted granted Critical
Publication of KR100254573B1 publication Critical patent/KR100254573B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

본 발명은, 활성성분에 불투과성인 뒷층, 40 내지 90중량%의 중합체 재료 및 0.1내지 20중량%의 피소스티그민 기재 또는 이것의 약제학적으로 허용될 수 있는 염을 함유하는 접착성 저장층, 및 저장층을 덮은 제거할 수 있는 보호층으로 이루어진, 피부를 통해 피소스티그민을 투여하기 위한 경피 치료계에 관한 것이다. 저장층은 아크릴레이트 및/또는 메타크릴레이트 중합체 재료, 및 히드록실기를 함유하고 1.1내지 12.0의 HLB 값을 갖는 0. 1내지 40중량%의 가소제를 함유한다.

Description

피부를 통해 피소스티그민을 투여하기 위한 경피치료계, 및 이러한 계의 제조방법(TRANSDERMAL THERAPEUTIC SYSTEM FOR ADMINISTERING PHYSOSTIGMIN THROUGH THE SKIN〈 AND A METHOD OF PRODUCING THE SYSTEM)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 활성성분에 불투과성인 뒷층, 40내지 90중량%의 중합체 재료 및 0.1내지 20중량% 피소스티그민 기재 또는 이것의 약제학적으로 허용될 수 있는 염중 하나를 함유하는 압력-민감성 저장층 및 저장층을 덮는 제거할 수 있는 보호층으로 구성되며, 저장층이 아크릴레이트 및/또는 메타크릴레이트에 근거한 중합체 재료 및 0.1내지 40중량%의 1.1내지 12.0의 HLB 값을 갖는 히드록실기-함유 연화제를 함유함을 특징으로 하는 경피치료계.
  2. 제1항에 있어서, 저장층이 중합체 재료로서 2-에틸헥실 아클릴레이트, 비닐 아세테이트 및 아크릴산 에스테르의 아크릴레이트 공중합체를 함유함을 특징으로 하는 경피치료계.
  3. 제1항에 있어서, 메타크릴레이트를 주성분으로 하는 중합체 재료가 디메틸아미노에틸 메타크릴레이트 및 중성 메타크릴산 에스테르에 근거한 공중합체를 함유함을 특징으로 하는 경피치료계.
  4. 제1항에 있어서, 연화제가 1-도데칸올임을 특징으로 하는 경피치료계.
  5. 제1항에 있어서, 연화제가 2-옥틸 도데칸올임을 특징으로 하는 경피치료계.
  6. 제1항에 있어서, 연화제가 올레일 알코올임을 특징으로 하는 경피치료계.
  7. 불투과성 뒷층에, 40 내지 90중량%의 압력 민감성 저장층 및 0. 1내지 20중량%의 피소스티그민 또는 이것의 약제학적으로 허용될 수 있는 염중 하나를 활성성분으로서 함유하는 압력-민감성 저장층을 도포시키고, 이 층을 제거할 수 있는 보호층으로 덮는 것으로 이루어지며, 저장층을 위해, 아크릴레이트 및/또는 메타크릴레이트에 근거한 중합체 재료, 및 0. 1 내지 40중량%의 1. 1내지 12.0의 HLB 값을 갖는 히드록실기-함유 연화제로 이루어진 균일한 혼합물이 사용됨을 특징으로 하는, 제 1항 내지 6항 중 어느 한 항에 따르는 경피치료계의 제조방법.
  8. 제7항에 있어서, 활성성분을 용액중에서 접착성 저장층 성분과 함께 균일하게 혼합시키고, 활성성분에 불투과성인 뒷층위에 분무시킨 후, 존재한다면, 용매(들)을 제거하고, 계속해서 접착제층을 보호층으로 덮은 후, 라미네이트를 분리에 의해 개별적 TTS로 제조하고, 이것을 포장내에 밀봉시킴을 특징으로 하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950701873A 1992-11-12 1993-10-27 피부를 통해 피소스티그민을 투여하기 위한 경피치료계,및 이것의 제조방법 KR100254573B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4238223A DE4238223C1 (de) 1992-11-12 1992-11-12 Transdermales therapeutisches System zur Verabreichung von Physostigmin an die Haut und Verfahren zu dessen Herstellung
DEP4238223.8 1992-11-12
PCT/EP1993/002970 WO1994010999A1 (de) 1992-11-12 1993-10-27 Transdermales therapeutisches system zur verabreichung von physostigmin an die haut und verfahren zu dessen herstellung

Publications (2)

Publication Number Publication Date
KR950703948A true KR950703948A (ko) 1995-11-17
KR100254573B1 KR100254573B1 (ko) 2000-05-01

Family

ID=6472735

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950701873A KR100254573B1 (ko) 1992-11-12 1993-10-27 피부를 통해 피소스티그민을 투여하기 위한 경피치료계,및 이것의 제조방법

Country Status (32)

Country Link
US (1) US5698216A (ko)
EP (1) EP0667774B1 (ko)
JP (1) JP3407073B2 (ko)
KR (1) KR100254573B1 (ko)
CN (1) CN1088457A (ko)
AT (1) ATE156356T1 (ko)
AU (1) AU684256B2 (ko)
CA (1) CA2147274C (ko)
CZ (1) CZ284008B6 (ko)
DE (2) DE4238223C1 (ko)
DK (1) DK0667774T3 (ko)
EE (1) EE03135B1 (ko)
EG (1) EG20527A (ko)
ES (1) ES2105334T3 (ko)
FI (1) FI952269A (ko)
GR (1) GR3024720T3 (ko)
HR (1) HRP931391B1 (ko)
HU (1) HUT72963A (ko)
IL (1) IL107547A (ko)
LT (1) LT3107B (ko)
LV (1) LV10749B (ko)
MD (1) MD937C2 (ko)
MY (1) MY111373A (ko)
NO (1) NO306760B1 (ko)
NZ (1) NZ257136A (ko)
PL (1) PL172999B1 (ko)
RU (1) RU2108812C1 (ko)
SI (1) SI9300589A (ko)
SK (1) SK280185B6 (ko)
WO (1) WO1994010999A1 (ko)
YU (1) YU71293A (ko)
ZA (1) ZA938413B (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4446600A1 (de) * 1994-12-24 1996-06-27 Lohmann Therapie Syst Lts Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen
DE19828273B4 (de) * 1998-06-25 2005-02-24 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System, enthaltend Hormone und Kristallisationsinhibitoren
DE19923551A1 (de) * 1999-05-21 2000-11-30 Lohmann Therapie Syst Lts Pharmazeutisches Präparat mit dem Wirkstoff Diamorphin und seine Verwendung in einem Verfahren zur Behandlung der Opiatsucht
AT500143A1 (de) * 2004-04-22 2005-11-15 Sanochemia Pharmazeutika Ag Cholinesterase-inhibitoren in liposomen sowie deren herstellung und verwendung

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3921363A (en) 1974-05-17 1975-11-25 Preston Metal & Roofing Prod Cross member with end connector
IL72684A (en) * 1984-08-14 1989-02-28 Israel State Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs
US4680172A (en) 1985-03-05 1987-07-14 Ciba-Geigy Corporation Devices and methods for treating memory impairment
DE3843239C1 (ko) 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
DE3843238C1 (ko) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
US5350581A (en) * 1989-12-14 1994-09-27 Pharmetrix Corporation Method for manufacturing transdermal devices
NZ237241A (en) * 1990-03-02 1993-11-25 Pharmetrix Corp Method for increasing the storage stability of physostigmine
WO1991015176A1 (en) * 1990-04-06 1991-10-17 Pharmetrix Corporation Device and method for enhanced administration of physostigmine
JP4355469B2 (ja) * 2002-03-08 2009-11-04 日本碍子株式会社 アルミナ担持担体、触媒体及びアルミナ担持担体の製造方法

Also Published As

Publication number Publication date
US5698216A (en) 1997-12-16
CA2147274C (en) 2005-12-13
DE4238223C1 (de) 1994-05-26
LV10749B (en) 1996-06-20
MD937B2 (ko) 1998-03-31
KR100254573B1 (ko) 2000-05-01
NO951864D0 (no) 1995-05-11
PL172999B1 (pl) 1998-01-30
PL308531A1 (en) 1995-08-21
HUT72963A (en) 1996-06-28
YU71293A (sh) 1996-07-24
IL107547A (en) 1996-12-05
FI952269A0 (fi) 1995-05-10
EP0667774A1 (de) 1995-08-23
SK280185B6 (sk) 1999-09-10
CN1088457A (zh) 1994-06-29
EE03135B1 (et) 1998-12-15
GR3024720T3 (en) 1997-12-31
ATE156356T1 (de) 1997-08-15
HU9501390D0 (en) 1995-06-28
HRP931391B1 (en) 1999-12-31
MD940311A (en) 1998-03-31
SK59395A3 (en) 1996-05-08
DK0667774T3 (da) 1998-03-23
LTIP1469A (en) 1994-06-15
WO1994010999A1 (de) 1994-05-26
CZ284008B6 (cs) 1998-07-15
DE59307089D1 (de) 1997-09-11
CA2147274A1 (en) 1994-05-26
CZ124495A3 (en) 1996-01-17
LT3107B (en) 1994-12-27
NZ257136A (en) 1996-07-26
IL107547A0 (en) 1994-02-27
LV10749A (lv) 1995-08-20
ES2105334T3 (es) 1997-10-16
EG20527A (en) 1999-06-30
FI952269A (fi) 1995-05-10
SI9300589A (en) 1994-06-30
RU2108812C1 (ru) 1998-04-20
MD937C2 (ro) 1999-01-31
NO951864L (no) 1995-05-11
EP0667774B1 (de) 1997-08-06
MY111373A (en) 1999-12-31
ZA938413B (en) 1994-06-09
AU5338594A (en) 1994-06-08
NO306760B1 (no) 1999-12-20
AU684256B2 (en) 1997-12-11
JPH08502986A (ja) 1996-04-02
HRP931391A2 (en) 1995-02-28
JP3407073B2 (ja) 2003-05-19

Similar Documents

Publication Publication Date Title
RU2098083C1 (ru) Способ седативного воздействия на пациента и трансдермальная терапевтическая система
AU678237B2 (en) Active substance-containing plaster
CA2459483C (en) Plaster for the treatment of dysfunctions and disorders of nail growth
US5306503A (en) Patch with a high content of softening ingredients
ES2237415T5 (es) Composiciones dermicas.
US20050187212A1 (en) Pharmaceutical composition for topical delivery of meloxicam
JP2655983B2 (ja) チロシナーゼ抑制活性を有する薬物の安定性を改善する方法、及び、皮膚美白用貼付剤
JPH08505632A (ja) 活性物質としてガランタミンを有する経皮医療システム
WO2006028863A1 (en) Transdermal antiemesis delivery system, method and composition therefor
CA2844288C (en) Transdermal therapeutic system for 5-aminolevulinic acid hydrochloride
JPH08143451A (ja) 経皮吸収製剤
JP4430120B2 (ja) 抗真菌症用貼付剤
JP5224163B2 (ja) 経皮吸収テープ製剤
KR100473677B1 (ko) 물리적 특성이 향상된 폴리아크릴레이트 매트릭스를 구비한 경피 또는 국소 플래스터 시스템
KR950703948A (ko) 피부를 통해 피소스티그민을 투여하기 위한 경피치료계, 및 이러한 계의 제조방법(transdermal therapeutic system for administering physostigmin through the skin〈 and a method of producing the system)
JPH02270818A (ja) ポリウレタンフィルムを支持体とする貼付剤
KR101353478B1 (ko) 펜타닐을 함유하는 경피투여용 패취 제제
JPH03291218A (ja) 貼付剤
JP3242324B2 (ja) ニトログリセリン経皮吸収型製剤
RU95113504A (ru) Трансдермальная терапевтическая система и способ ее получения
KR970705995A (ko) 스코폴아민 패치
JPH10287557A (ja) 貼付剤
JP2009242424A (ja) 抗真菌症用貼付剤
JPH10182445A (ja) 外用貼付剤
JPH0348618A (ja) 経皮吸収貼付剤

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee